Researchers are invited to submit their concept proposal. Concept proposals, inclusive of preclinical, clinical and outcomes research, will be reviewed collectively by the Immunocore ESR Committee based on scientific merit and alignment with Immunocore’s areas of research interest. CLICK HERE to see current Areas of Interest

When submitting a proposal, you will be guided through the electronic submission process by instructions and help options. All proposals submitted will be reviewed by the respective Therapeutic Area (TA) cross functional team. Submitted proposals go through a two-stage process. Please note that Immunocore's interest in a proposal does not guarantee we will ultimately support the submitted protocol.

1) Concept Review

A Concept is a brief summary of your proposal. It must contain an adequate level of information for Immunocore to determine whether it will be of interest to the program. If the Concept is found to be of interest, Immunocore will request a Full Protocol for further review.

With the submission, please include the requested information, such as type of support (drug, funding or both), budget (including Direct, Indirect, per Patient Costs, and Fees), Organizations W-9, Investigators (CV), Overview/Hypothesis, Background/Rationale, Objectives, and Length of Study. Support in the form of funding and/or drug, if any, will be granted based on scientific merit. If funding is being sought, the proposed budget must be reasonable and appropriate for the study. Scientific expertise will also be considered.

2) Protocol Review

Prior to protocol submission and review, a confidential disclosure agreement will be initiated. A Protocol submission must contain full details of the proposed research study, as a MS Word Document, to make a final determination for support. The Protocol must include Background & Rationale, Study Design, Study Objectives/Endpoints, Treatment Plan, Study Duration, Study Procedures, Safety Reporting including SAEs, AESI and Pregnancy and Statistical Considerations including the sample size justification. The Protocol submission entry must also include planned study timelines, final budget, as well as a publication plan.

The final budget should not exceed the initially submitted budget with the concept. Immunocore’s financial and product support are subject to execution of Immunocore's standard research agreement. Prior to proceeding with a proposal, please review Immunocores's required legal terms with your institution to ensure alignment. As required by law, we disclose financial support provided to researchers and their institutions.

Requirements that need to be met for Immunocore to consider support of your proposal (and potential ensuing protocol) include, but are not limited to the following:

• You are qualified in terms of background, education, and experience to conduct and complete the proposed research
• You are not debarred, disqualified, restricted or excluded from engaging in activities relating to development or approval of drugs by any regulatory authority
• If research involves treatment of patients, your license is active
• You assume all responsibilities and obligations to comply with all relevant laws and regulatory requirements (e.g., Good Clinical Practice and safety reporting regulations)
• You or your appointed representative holds the IND or equivalent clinical trial authorization (as applicable)
• You provide safety reports to Immunocore, in accordance with the research agreement
• You provide study status updates in accordance with the research agreement
• You submit the final study report and manuscript, as applicable and in accordance with the research agreement

Immunocore requires that the following documents are in place before the support can be initiated:

• fully executed agreement between the sponsor and Immunocore
• an EC/IRB and/or health authority approval

All funding requests will be assessed to ensure that they do not exceed local fair market value. Funding requests for expenses not associated with the conduct of the study are strictly prohibited.